Smartwatch and ring take on the 12-Lead ECG in heart rhythm showdown

NCT ID NCT05298553

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether two wearable devices—the Apple Watch and the Skylab CART-I ring—can accurately detect atrial fibrillation and other irregular heart rhythms compared to the standard 12-lead ECG. Researchers recruited 500 adults from UK cardiology clinics. Each participant wore both devices and had their heart rhythm recorded simultaneously with the standard test. The goal was to see if the wearables' single-lead ECGs and automatic detection algorithms could match the gold standard. If successful, these devices could make it easier to spot hidden heart rhythm problems without a clinic visit.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Apple Watch and Skylab CART-I ring (wearable single-lead ECG devices)

What this could lead to

If these wearables prove accurate, they could help catch hidden heart rhythm problems earlier, potentially preventing strokes.

What could go wrong

This is a completed diagnostic study, not a treatment trial. The devices may not be as reliable as the gold-standard 12-lead ECG, and results may not apply to all patients.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Arrhythmias, Cardiac atrial fibrillation ventricular arrhythmias due to cardiac ryanodine receptor calcium release deficiency syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Oxford Univeristy Hospitals NHS Foundation Trust

    Oxford, Oxfordshire, OX89DU, United Kingdom

  • University Hospital Birmingham

    Birmingham, United Kingdom

  • University Hospital Southampton

    Southampton, United Kingdom